 Galera Therapeutics Inc NASDAQ: GRTX announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy SBRT for non-small cell lung cancer NSCLC. Enrollment is ongoing in the randomized, double. 